Navigation Links
R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
Date:3/10/2009

ere are more than 2,900 medicines in development in the U.S., including 750 compounds in development for cancer, 312 for heart disease and stroke, 150 for diabetes, 109 for HIV/AIDS and 91 for Alzheimer's disease and dementia.

"As we look toward the future of health care in America, we must remember that the incredible progress we make every day in research and development will be wasted if patients don't have access to our life-saving medicines," said Tauzin. "That's why we're committed to working toward comprehensive health care reform that offers health coverage to all Americans."

Burrill & Company computes R&D expenses among other key financial parameters on a quarterly basis, in its Burrill Report, for the universe of U.S. publicly listed biotech companies through its reports on the industry (sourced from company reports filed with the SEC). To create a comparable report additive to PhRMA's annual membership survey, Burrill applies a set of pre-determined criteria to their biotech research to identify and select non-member companies. Specifically:

      -- Companies must be based in the United States of America
      -- Companies must not be a member or member subsidiary of PhRMA and,
      -- Companies must meet the "human healthcare focus" test, i.e., their
         R&D expenses are principally for research and development of new
         medicines for healthcare.

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of leading industry conferences worldwide and publisher
'/>"/>

SOURCE Burrill & Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
2. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007
3. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
4. Frost & Sullivans Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells
5. Eiger BioPharmaceuticals Raises $7.1 Million A Round
6. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
7. Mach One Closes on Acquisition of Biopharmaceutical Design & Engineering Firm
8. TechniKroms Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical
9. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
10. Global Biopharmaceutical Leader in Peptide Research Expands Commitment in San Diego/U.S. With New R&D Facility and Ready-To-Market Prostate Cancer Treatment Degarelix
11. Mach One Executes Definitive Agreement to Acquire Biopharmaceutical Design & Engineering Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Exotic Automation & ... the launch of http://www.cng.exoticautomation.com , an ecommerce ... convenient way to purchase genuine OEM replacement CNG, ... , The new website provides owners of fleets ... access to high performance products for their vehicle ...
(Date:5/4/2015)... May 4, 2015 Many of us ... for certain infants with rare, inherited mutations of ... consequences of their impaired immune responses. ... identified an important role for calcium signaling in ... tuberculosis, the bacterium causing tuberculosis (TB). ...
(Date:5/4/2015)... TEL AVIV, Israel , May 4, 2015 /PRNewswire/ ... has filed its annual report on Form 20-F for ... U.S. Securities and Exchange Commission ("SEC"). The annual report ... for the development of antibodies in the area of ... antibodies with superior qualities of high specificity and binding ...
(Date:5/4/2015)... 2015 Genedata, a leading provider ... life science research, today announced the release of ... of its enterprise solution for biologics R&D. This ... efficient discovery and development of novel biotherapeutics. Version ... address protein optimization and developability requirements. Genedata will ...
Breaking Biology Technology:Exotic Automation & Supply Launches Ecommerce Website 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4
... CardioDex announces initial commercial use ... from commercial use of the device on 41 patients at ... and no complications. "We are very excited about these new ... for a major unmet medical need due to the increasing ...
... Pa., May 1, 2012  Discovery Laboratories, Inc. (NASDAQ: ... new pharmacoeconomic analysis demonstrating that the lower rate of ... , when compared with infants treated with Curosurf ® ... leading surfactants, also resulted in a potential hospital cost ...
... 2012 /PRNewswire-Asia/ -- 3SBio Inc. (NASDAQ: SSRX ) ... focused on researching, developing, manufacturing and marketing biopharmaceutical products, ... Report on Form 20-F for the fiscal year ended ... Commission on April 30, 2012. The annual report on ...
Cached Biology Technology:New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy 2New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy 3Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 2Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 3Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 4Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants 5
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... can produce biodiesel fuel from municipal sewage sludge that is ... conventional diesel refined from petroleum, according to an article in ... is the solid material left behind from the treatment of ... out in the article that demand for biodiesel has led ...
... part of a healthy diet, can increase the levels ... cholesterol, according to an international team of nutritional scientists., ... lowering lipids and lipoproteins, which are a risk factor ... nutrition, Penn State. "This new study shows an additional ...
... the lowly lamprey eel have identified an overlooked nervous ... circuitry in vertebrates such as birds, fishes and mammals. ... , online May 16, and highlighted in the magazine,s ... Illinois at Chicago professor of biological sciences and the ...
Cached Biology News:Pistachios offer multiple benefits 2Pistachios offer multiple benefits 3Parallel brainstem circuit discovery suggests new path in Parkinson's research 2
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... solid. PROTECT FROM LIGHT. Useful in cell activation experiments ... ≥98% by TLC. Soluble in DMSO or EtOH. ... 10 mM stock in DMSO is recommended. Microliter amounts ... O with rapid mixing (e.g. 10 μl into 5 ...
Monoclonal antibodies conjugated with rhodamine...
Biology Products: